FormalPara Key Points

Biosimilar to bevacizumab

Equivalent efficacy and similar tolerability to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC

Approved for same types of cancer for which bevacizumab is approved

1 Introduction

SB8 is a biosimilar of the monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. The product details are summarized in Table 1. SB8 is approved in the EU for same types of cancer as bevacizumab (Table 2) [1]. SB8 has similar physicochemical, functional and pharmacodynamic characteristics to those of reference bevacizumab [2, 3] and pharmacokinetic similarity of the agents has also been demonstrated [3, 4]. This article summarizes, from an EU perspective, the key features of SB8 and its clinical use in the treatment of various cancers, focusing on non-small cell lung cancer (NSCLC).

Table 1 SB8 product details
Full size table
Table 2 SB8 prescribing summary in the EU [1]a
Full size table

2 Clinical Pharmacology

SB8 has similar physiochemical characteristics and functional properties to those of reference bevacizumab (Table 3) [2, 3]. In vitro functional assay data are supported by comparable anti-tumour activity of SB8 and reference bevacizumab in a human NSCLC xenograft mice model [2].

Table 3 Biosimilarity summary of SB8
Full size table

Pharmacokinetic similarity of SB8 to EU-sourced bevacizumab was demonstrated in a randomized, double-blind, phase 1 pharmacokinetic study in healthy volunteers [4]. The 90% CI for geometric least squares means ratios for the primary endpoints of area under the concentration-time curve (AUC) from time zero to infinity, AUC from time zero to the last quantifiable concentration and the maximum observed serum concentrations (Cmax) were within the prespecified bioequivalence margin of 80.00–125.00% [4]. Furthermore, in a phase 3 study in patients with NSCLC (Sect. 3), Cmax and trough serum concentrations at cycles 1, 3, 5 and 7 were largely similar for SB8 and EU-sourced bevacizumab [3]. SB8 had a slightly lower exposure than reference bevacizumab, which did not impact the efficacy or safety of SB8 [2]. Based on the totality of all pharmacological data, bioequivalence of SB8 to EU-sourced reference bevacizumab was demonstrated [2].

SB8 was stable under extreme aseptic conditions [5]. Unopened SB8 vials and in-use SB8 (opened vials and diluted product) at room temperature or refrigerated conditions did not show clinically relevant changes in physicochemical stability and functional characteristics and potential safety-related properties (Table 1) [5].

3 Clinical Efficacy

SB8 showed equivalent efficacy to reference bevacizumab in a randomized, double-blind, multicentre phase 3 study in patients with metastatic or recurrent nonsquamous NSCLC (reference indication) [3]. Eligible patients were adults (age ≥ 18 years) with histologically and/or cytologically confirmed disease who had ≥ 1 measurable lesion (defined by RECIST version 1.1), Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of ≥ 3 months. Patients who received systemic treatment for metastatic or recurrent NSCLC, systemic neoadjuvant or adjuvant chemotherapy within 12 months before randomization, or VEGF- or epidermal growth factor receptor-targeting agents were among those excluded. Stratified by age (< 70 and ≥ 70 years) and gender, patients received intravenous SB8 (n = 379) or reference bevacizumab (n = 384) 15 mg/kg, coadministered with paclitaxel and carboplatin, every 3 weeks for up to six cycles (induction treatment). Patients with complete response (CR), partial response (PR) or stable disease at the end of induction treatment received maintenance therapy with SB8 or reference bevacizumab every 3 weeks until disease progression or unacceptable toxicity (Fig. 1) [3].

Fig. 1
figure 1

Design of the SB8-G31-NSCLC trial [3]. BEV reference bevacizumab, CBP carboplatin, PTX paclitaxel, wk(s) week(s)

Full size image

The primary endpoint was best overall response rate [ORR] (CR + PR, based on RECIST version 1.1) during the induction treatment period by 24 weeks [3]. Equivalence was established if the 2-sided 90% CI for the best ORR risk ratio was within 0.737–1.357 in the full analysis set (FAS) or if the 2-sided 95% CI for the best ORR risk difference was within − 12.5% to 12.5% in the per-protocol set (PPS) [3].

Baseline demographics and disease characteristics were similar in SB8 and reference bevacizumab groups [3]. Mean age was 60.1 years and 66.6% of patients were men; the majority were White (91.1%), had an ECOG performance status of 1 (72.0%) and had stage IV disease (99.0%). The median duration of disease was 1.1 months [3].

SB8 was equivalent to reference bevacizumab [3]. In the FAS, the best ORR was 47.6 and 42.8%, respectively; the best ORR risk ratio (1.11; 90% CI 0.975–1.269) was within the prespecified equivalence margin. In the PPS, the best ORR was 50.1% and 44.8%, respectively; the best ORR risk difference was 5.3% (95% CI − 2.2% to 12.9%) and thus, only the lower margin, but not the upper margin, was within the prespecified equivalence margin. The robustness of the primary analysis was supported by sensitivity analyses, using age groups (< 70, ≥ 70 years), gender (male, female), geographic region (EU, non-EU) and treatment groups as covariates [3].

In the FAS, at the end of study, SB8 was also comparable to reference bevacizumab with respect to median progression-free survival [PFS] (8.50 vs 7.90 months; HR 0.99; 95% CI, 0.83–1.18), median overall survival [OS] (14.90 vs 15.80 months; HR 1.03; 95% CI, 0.83–1.28), median duration of response (7.70 vs 7.00 months; HR 1.05; 95% CI 0.81–1.37), 12-month PFS rate (34 vs 30%) and 12-month OS rate (61 vs 62%) [3].

In exploratory analyses, 95% CIs for the best ORR risk difference between the SB8 and reference bevacizumab groups by weeks 11 and 17 of the induction treatment was within the prespecified equivalence margin in the PPS [6]. Similar results were seen by week 24 in subgroups based on age, gender, race, geographical region, ECOG performance status, smoking status, cancer type and distant metastases [6]. SB8 was also comparable to reference bevacizumab with respect to the mean maximum percentage change from baseline in tumour burden by weeks 11, 17 and 24 of the induction treatment period [3, 6].

4 Tolerability and Safety

The tolerability and safety profile of SB8 was generally similar to that of reference bevacizumab in the phase 3 trial [3]. The mean number of treatment cycles was similar in SB8 and reference bevacizumab groups during induction period (4.8 vs 4.8) and maintenance period (9.3 vs 9.1). In the safety set (n = 378 and 380 in SB8 and reference bevacizumab groups), treatment-emergent adverse events (TEAEs) occurred in the majority of patients (92.1 vs 91.1%), with grade ≥ 3 TEAEs reported in 46.0 and 40.8% of patients. The most common (incidence ≥ 20%) TEAEs of any grade were alopecia (48.7 vs 48.2%), anaemia (24.3 vs 23.7%) and nausea (19.6 vs 21.1%); the most common grade ≥ 3 TEAEs were neutropenia (8.7 vs 9.5%), hypertension (6.3 vs 3.7%), anaemia (4.8 vs 5.5%) and decreased neutrophil count (4.0 vs 3.2%). TEAEs of special interest were grade ≥ 3 hypertension (7.7 vs 4.2%) and grade ≥ 2+ proteinuria on urine dipstick/urinalysis (0.5% vs 1.8%); other important TEAEs with an incidence ≥ 2% included hypersensitivity reactions/infusion-related reactions (12.7 vs. 12.4%), bleeding/haemorrhage (11.4 vs. 11.8%), pulmonary haemorrhage (3.4 vs 4.5%), venous thromboembolic events (3.2 vs. 3.7%), and congestive heart failure (2.1 vs. 2.4%). Serious TEAEs occurred in 19.8 and 21.3% of SB8 and reference bevacizumab recipients, with 13.2 and 9.5% of patients discontinuing study medication because of TEAEs. The incidence of death (regardless of causality) was 5.8 and 7.1% [3].

5 Immunogenicity

The immunogenicity of SB8 was similar to that of reference bevacizumab, with no new safety signals attributable to the immunogenicity of SB8 [2, 3]. In the phase 3 trial, antidrug antibodies (ADAs) were detected in 16.1 and 11.0% of patients in the SB8 and reference bevacizumab groups up to the end of treatment [3]. Neutralizing antibodies were detected in 7.1 and 8.3% of patients at the end of treatment [2]. Best ORRs tend to be higher with SB8 versus reference bevacizumab in ADA-positive patients, while the opposite was true for ADA-negative patients. ADAs had no clinically relevant impact on PFS and duration of response in both groups. In the SB8 group, two cases of treatment discontinuations (anaphylaxis and hypersensitivity) appeared to be related to immunogenicity [2].

6 Conclusion

SB8 is a bevacizumab biosimilar with similar efficacy, tolerability, safety, physiochemical characteristics and functional properties to the reference product (Table 3). Based on physicochemical and functional analyses, as well as clinical data in patients with metastatic or recurrent nonsquamous NSCLC (Table 3), SB8 is approved in the EU for the same types of cancer for which bevacizumab is approved (Table 2).